Aramayo Oscar Best Actor Nomination Odds Fall to 4% Post-Ceremony

---

Robert Aramayo's Oscar Nomination Odds Hit 4%, but the Race Was Already Run

The 2026 Academy Awards ceremony aired on March 15. Michael B. Jordan took home the Best Actor statuette for "Sinners." The credits rolled. The ballots were counted months ago. And yet, on Kalshi and Polymarket, you can still trade a contract asking whether Robert Aramayo will receive an Oscar nomination for Best Actor, with resolution set for January 21, 2027.

That contract now sits at 4% on Kalshi and 5% on Polymarket, down from 30% just three days ago, a 25 percentage-point collapse. The move is not a reaction to new information about Aramayo's talent, campaign strategy, or critical reception. It is the market catching up to a fact that has been public for months: the Academy nominated Timothée Chalamet, Leonardo DiCaprio, Ethan Hawke, Michael B. Jordan, and Wagner Moura. Aramayo's name was never called.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Robert Aramayo

Consensus YES price across 2 venues

10%average

KalshiBest YES price12¢Polymarket12.2¢

Dominic Sessa

Consensus YES price across 1 venues

10%average

KalshiBest YES price10¢

Keanu Reeves

Consensus YES price across 1 venues

8%average

KalshiBest YES price9¢

Channing Tatum

Consensus YES price across 1 venues

7%average

KalshiBest YES price8¢

Current new-user offer · Kalshi

Get a $35 trading bonusCode PRED35

New users only. Eligibility restrictions and terms apply.

View current offer

Before explaining why the market still holds a residual 4% rather than resolving at zero, it is worth reconstructing what the original 30% was actually betting on, and how seriously the industry treated Aramayo's candidacy before the ceremony.

---

How Robert Aramayo Reached 30%: The Performance That Generated Real Oscar Buzz

Aramayo's performance in "I Swear," a film centered on John Davidson, a Scottish man living with severe Tourette's syndrome, drew the kind of attention that fuels genuine Oscar campaigns. The role demanded physical and emotional precision, and Aramayo delivered at a level the British academy recognized with its highest individual honor: Best Leading Actor at the 2026 BAFTA Film Awards.

A BAFTA Leading Actor win is one of the strongest precursor signals in awards analytics. In recent cycles, BAFTA winners have landed Oscar nominations at a high rate. That correlation, combined with strong critical reviews, pushed Aramayo's implied probability to 30% on prediction platforms. The market was not speculating wildly. It was processing a legitimate awards-season signal from one of the three most predictive precursor ceremonies.

The 30% reflected a real competitive position. Aramayo had international critical support, a transformative physical performance (the kind Academy voters historically reward), and a BAFTA trophy to anchor his campaign narrative. His odds were not inflated by hype alone.

---

Nomination Morning Came and Went: Why Aramayo's Name Was Not Called

The 2026 Oscar nominations announcement sealed the outcome. The Best Actor category went to five performers whose campaigns had deeper traction with the Academy's acting branch: Chalamet for "Marty Supreme," DiCaprio for "One Battle After Another," Hawke for "Blue Moon," Jordan for "Sinners," and Moura for "The Secret Agent."

Aramayo's omission was notable precisely because of his BAFTA win. Several factors likely contributed. The Best Actor field in 2026 was unusually stacked with high-profile names carrying decades of Academy goodwill. DiCaprio and Hawke each brought legacy narratives. Jordan's dual-role performance in "Sinners" generated momentum that proved unstoppable (he ultimately won the Oscar). Chalamet and Moura rounded out a category with no obvious weak link. Aramayo, a younger actor without prior Oscar history, may have been squeezed out by a combination of vote-splitting among international performances and the sheer star power of his competitors.

The market reaction was immediate and severe. The 30% to 4% drop represents the contract adjusting from "plausible contender" to "this already did not happen."

---

The Case for 4% Not Being Zero

Here is where the counter-argument deserves genuine consideration. Why does the contract trade at 4% instead of 0% for an event that already failed to occur?

The answer lies in resolution mechanics, not awards-season uncertainty. The market's official resolution date is January 21, 2027, which likely corresponds to the next cycle's nomination announcements. If the contract is written ambiguously enough to encompass any Oscar nomination for Best Actor (not exclusively the 2026 cycle), then the residual 4% could represent a thin bet that Aramayo receives a nomination for a different performance in the 2027 cycle. This is not impossible. Actors who narrowly miss one year sometimes ride residual goodwill into the next if they have a qualifying release.

However, this interpretation stretches the market's intent. More likely, the 4% reflects the friction cost of illiquid contracts approaching expiration: a few stale limit orders, minimal trading activity, and the structural reality that prediction markets rarely price anything at true zero until formal resolution.

---

Robert Aramayo Best Actor Nomination Odds: From Contender to Historical Artifact

The three-day chart tells a clean story. The contract held near 30% while awards-season uncertainty persisted, then collapsed to its period low of 4% as the market digested the finality of the nomination list. The Kalshi-Polymarket spread (4% vs. 5%) is tight enough to confirm both platforms are pricing the same information. There is no arbitrage opportunity here, just two platforms agreeing that this contract is functionally dead.

---

What This Market Really Tells Us

Robert Aramayo's prediction market arc is a case study in how awards-season contracts behave after resolution. The 30% peak was analytically defensible. The BAFTA win was a strong signal. The competitive field, featuring Jordan, DiCaprio, Chalamet, Hawke, and Moura, was simply too deep. Aramayo's exclusion was not a rebuke of his performance but a reflection of a historically crowded category.

For traders still holding "Yes" contracts at 4%, the position is essentially a call option on a clerical error or a market misspecification. The Academy is not going to retroactively add a sixth nominee. The 2026 ceremony is over. Jordan won. The only remaining question is whether this contract resolves on January 21, 2027, at its expected value of zero, or whether some edge-case interpretation of the resolution criteria produces a different outcome. At 4%, the market is pricing that ambiguity, not Aramayo's talent.